Find Qualified API Suppliers for Off-Patent Drugs: The Patent & Regulatory Intelligence Playbook
The $236 Billion Race Most Procurement Teams Are Losing Between 2025 and 2030, more than $236 billion in branded pharmaceutical […]
CDMO Project Management: The Definitive Playbook for Pharma IP Teams, R&D Leads, and Institutional Investors
I. Market Context: Why the CDMO Sector Is Repricing The global pharmaceutical CDMO market hit approximately $181.93 billion in 2025,
Your Drug’s Patent Expired. Now What? The Complete Strategic Guide to Patent Cliffs, Lifecycle Defense, and Post-Exclusivity Competition
1. The Cliff Everyone Sees Coming — and Still Falls Off Every branded pharmaceutical product carries a date of death.
Designing Around the Picket Fence: A Strategic Guide to Freedom-to-Operate for Generic Drugs
An investigative analysis of patent thickets, design-around strategies, and competitive intelligence for pharmaceutical generics manufacturers The Wall Every Generic Manufacturer
Drug Patents in Africa: Exactly How Long They Last
A country-by-country guide for pharmaceutical executives, generic manufacturers, and IP professionals operating across 54 markets The Patent Map Nobody Prints
Drug Patents in Africa: Exactly How Long They Last Read Post »
Green Light to Launch: The Definitive Step-by-Step FTO Analysis Guide for New Drug Products
How to conduct a freedom-to-operate analysis that holds up in court, survives investor due diligence, and actually protects your pipeline
Value a Biotech Like a Pro: The Metrics That Actually Move Price Targets
An Investigative Analysis of Pharmaceutical and Biotech Valuation Frameworks Why Most Biotech Valuations Get It Wrong Every quarter, analysts revise
Value a Biotech Like a Pro: The Metrics That Actually Move Price Targets Read Post »
Patent vs. Regulatory Exclusivity: The Drug Industry’s Two-Layer Protection System Explained
What You Actually Need to Know About the Dual Shield Most people conflate drug patents with drug exclusivity. They are
First to File. First to Profit: The Complete Guide to Paragraph IV Certifications and 180-Day Exclusivity
How generic drug companies legally exploit the Hatch-Waxman framework to generate billion-dollar windfalls — and how brand manufacturers fight back
